{"DataElement":{"publicId":"4809711","version":"1","preferredName":"Disease or Disorder Best Outcome of Therapy Waldenstrom Macroglobulinemia Chemosensitivity Type","preferredDefinition":"A description of the best response to therapy for the sensitivity of  waldenstrom's macroglobulinem.","longName":"2946463v1.0:4809659v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2946463","version":"1","preferredName":"Disease or Disorder Best Outcome of Therapy","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Having the most positive qualities._The result of therapy for a given disease or condition in a patient or group of patients.","longName":"2404658v1.0:3194600v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2404658","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0651-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"PWEST","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3194600","version":"1","preferredName":"Best Outcome of Therapy","preferredDefinition":"Having the most positive qualities.:The result of therapy for a given disease or condition in a patient or group of patients.","longName":"C25432:C18919","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Best","conceptCode":"C25432","definition":"Having the most positive qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome of Therapy","conceptCode":"C18919","definition":"The result of therapy for a given disease or condition in a patient or group of patients.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D80CD45-BE7A-5B19-E040-BB89AD430E80","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-03-02","modifiedBy":"ONEDATA","dateModified":"2011-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"747EBAC6-25E8-A734-E040-BB89AD43588E","latestVersionIndicator":"Yes","beginDate":"2009-09-26","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-09-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4809659","version":"1","preferredName":"Waldenstrom Macroglobulinemia Chemosensitivity Type","preferredDefinition":"Lymphoplasmacytic lymphoma associated with bone marrow involvement and IgM monoclonal gammopathy._Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better._Something distinguishable as an identifiable class based on common qualities.","longName":"4809659v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Not applicable","valueDescription":"Not applicable","ValueMeaning":{"publicId":"4809671","version":"1","preferredName":"Not applicable","longName":"4809671","preferredDefinition":"No systemic therapy prior to the preparative regimen, or systemic therapy ended greater than 6 months prior to the preparative regimen","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"154248BD-575D-88FE-E050-BB89AD435416","latestVersionIndicator":"Yes","beginDate":"2015-05-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-05-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"154248BD-5775-88FE-E050-BB89AD435416","beginDate":"2015-05-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-05-04","modifiedBy":"ONEDATA","dateModified":"2015-05-04","deletedIndicator":"No"},{"value":"Resistant","valueDescription":"Resistant","ValueMeaning":{"publicId":"4809672","version":"1","preferredName":"Resistant","longName":"4809672","preferredDefinition":"Less than 50% reduction in measurable tumor cell mass, bone marrow and serum paraprotein","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"154248BD-577F-88FE-E050-BB89AD435416","latestVersionIndicator":"Yes","beginDate":"2015-05-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-05-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"154248BD-5797-88FE-E050-BB89AD435416","beginDate":"2015-05-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-05-04","modifiedBy":"ONEDATA","dateModified":"2015-05-04","deletedIndicator":"No"},{"value":"Sensitive","valueDescription":"Sensitive","ValueMeaning":{"publicId":"4809673","version":"1","preferredName":"Sensitive","longName":"4809673","preferredDefinition":"Greater than or equal to 50% reduction in measurable tumor cell mass, bone marrow and serum paraprotein","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"154248BD-57A1-88FE-E050-BB89AD435416","latestVersionIndicator":"Yes","beginDate":"2015-05-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-05-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"154248BD-57B9-88FE-E050-BB89AD435416","beginDate":"2015-05-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-05-04","modifiedBy":"ONEDATA","dateModified":"2015-05-04","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2565695","version":"1","preferredName":"Unknown","longName":"2565695","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CDAC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-02-26","endDate":null,"createdBy":"MEDVEDOH","dateCreated":"2003-02-26","modifiedBy":"MMADDINENI","dateModified":"2024-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"15418464-C9BB-940F-E050-BB89AD436363","beginDate":"2015-04-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-05-04","modifiedBy":"ONEDATA","dateModified":"2015-05-04","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"4809658","version":"1","preferredName":"Waldenstrom Macroglobulinemia Chemosensitivity Type","preferredDefinition":"Lymphoplasmacytic lymphoma associated with bone marrow involvement and IgM monoclonal gammopathy.:Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better.:Something distinguishable as an identifiable class based on common qualities.","longName":"C80307:C71488:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Waldenstrom Macroglobulinemia","conceptCode":"C80307","definition":"Lymphoplasmacytic lymphoma associated with bone marrow involvement and IgM monoclonal gammopathy.","evsSource":"RADLEX_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Chemosensitivity","conceptCode":"C71488","definition":"Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"15418464-C994-940F-E050-BB89AD436363","latestVersionIndicator":"Yes","beginDate":"2015-05-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-05-04","modifiedBy":"ONEDATA","dateModified":"2015-05-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"15418464-C9A5-940F-E050-BB89AD436363","latestVersionIndicator":"Yes","beginDate":"2015-05-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-05-04","modifiedBy":"KUMMEROA","dateModified":"2021-04-27","changeDescription":". 2021-4-27 ak OK to release per WZ.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"What was the best outcome of","type":"Preferred Question Text","description":"What was the best outcome of therapy for the sensitivity of waldenstrom's macroglobulinemia?","url":null,"context":"NHLBI"},{"name":"Best response to line of therapy","type":"Alternate Question Text","description":"Best response to line of therapy","url":null,"context":"NHLBI"},{"name":"Best response to line of therapy","type":"Application Standard Question Text","description":"Best response to line of therapy","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"154248BD-584E-88FE-E050-BB89AD435416","latestVersionIndicator":"Yes","beginDate":"2015-05-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-05-04","modifiedBy":"KUMMEROA","dateModified":"2021-04-27","changeDescription":". 2021-4-27 ak OK to release per WZ. System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}